Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.

It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.

Read more below.




To see our most recent news,
follow us on LinkedIn

Go to our LinkedIn page